Cas:73220-26-5 1-methoxy-2-(methoxymethoxy)benzene manufacturer & supplier

Chemical Name:1-methoxy-2-(methoxymethoxy)benzene

CAS.NO:73220-26-5

Synonyms:2-methoxymethoxy-3-methoxybenzene;Benzene,1-methoxy-2-(methoxymethoxy);2-methoxyphenyl-methoxymethylether;O’-Methyl-O-methoxymethyl-brenzcatechin;1-methoxy-2-methoxymethoxybenzene

Molecular Formula:C₉H₁₂O₃

Molecular Weight:168.19000

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:27.69000

Exact Mass:168.07900

LogP:1.67790

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2-methoxymethoxy-3-methoxybenzene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-methoxy-2-methoxymethoxybenzene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-methoxyphenyl-methoxymethylether Use and application,Benzene,1-methoxy-2-(methoxymethoxy) technical grade,usp/ep/jp grade.

Related News: The target screening performed by Retrogenix will focus on hundreds of novel, prioritized antibodies in Resonant��s collection. 1-methoxy-2-(methoxymethoxy)benzene manufacturer This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.? 1-methoxy-2-(methoxymethoxy)benzene supplier Under the high pressure of environmental protection, if Chinese API companies want to achieve sustainable operation, they must recognize the current situation, increase environmental investment, and carry out industrial upgrades, focusing on new product development, process improvement, CMO business and new technology research. And other businesses to carry out work to improve safety, environmental protection, quality, cost and other capabilities, so as to seize structural opportunities. 1-methoxy-2-(methoxymethoxy)benzene vendor The target screening performed by Retrogenix will focus on hundreds of novel, prioritized antibodies in Resonant��s collection. 1-methoxy-2-(methoxymethoxy)benzene factory This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?